logo
The FDA Just Discovered A New Uncomfortable Side Effect For This Popular Allergy Med

The FDA Just Discovered A New Uncomfortable Side Effect For This Popular Allergy Med

Yahoo18-06-2025
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links."
Allergy season is in full swing, and chances are, if you're one of the 25 percent of adults who suffer from seasonal sniffles, you're reaching for your trusty meds. Zyrtec is a super popular over-the-counter option because it's pretty darn reliable to treat your symptoms. But, as with any other drug, it's important to keep Zyrtec side effects in mind so you can get all the benefits while minimizing any potential downsides.
Zyrtec is an antihistamine and it blocks histamines to stop allergic reactions, says Virginia Boomershine, an ambulatory clinical pharmacy regional senior manager for Banner Pharmacy Services. Histamines are the culprits behind all those pesky allergy symptoms, like itchy, watery eyes, runny nose, scratchy throat, and sneezing.
The good news is there are fewer side effects from Zyrtec compared to first-generation antihistamines such as Benadryl (which you actually shouldn't be taking at all), and it's relatively safe even at higher than standard doses for most people, says Jennifer Toh, MD, an allergist and immunologist at ENT and Allergy Associates.
Below, docs share *all* the possible side effects you might experience on the med. Take note: most of the entries below include the word "rare." That's because side effects on Zyrtec are uncommon. Any side effects are typically mild, and a majority of people can take the medication with no issues, adds Purvi Parikh, MD, an allergist and immunologist at Allergy & Asthma Network. Keep reading to find out whether this medication is right for you and what you can do about the potential side effects.
Meet the experts: Jennifer Toh, MD, is an allergist and immunologist at ENT and Allergy Associates. Purvi Parikh, MD, is an allergist and immunologist at Allergy & Asthma Network. Virginia Boomershine is an ambulatory clinical pharmacy regional senior manager for Banner Pharmacy Services. Maria Shtessel, MD, is an assistant professor of medicine, division of clinical immunology at Mount Sinai. Robert Eitches, MD, is an allergist at Tower Allergy.
It's best to be aware of potential Zyrtec side effects—especially if you're planning on popping the stuff on the reg over the next few months.If you've ever slept 14 hours after popping a Benadryl, you're well aware that some allergy meds can seriously knock you out. That's not as common with Zyrtec, but 11 to 14 percent of people do report feeling sleepy after taking it, making it the most common side effect reported, says Boomershine.
Since the effects of Zyrtec last 24 hours, drowsiness can hit at any time. Avoid alcohol and be careful about driving if the med hits you with the sleepies, per the Zyrtec site.When you have an allergic response, your tissue secretes more fluid (hello runny nose and watery eyes). Antihistamines, therefore, dry you up, which means that dry mouth is a possibility—but only a small one. Less than 10 percent of Zyrtec poppers will wind up with dry mouth, says Boomershine.
Drinking water will help, she says, as will switching to an alcohol-free mouthwash, as that ingredient also dries you out.Dizziness can be a rare potential side effect and may disappear after your body adjusts to the medication, per the Mayo Clinic. Give it time, but always check in with your doctor if you're concerned. And, just like with drowsiness, hold off on driving if you're feeling wobbly.Zyrtec may cause insomnia because the medicine can block acetylcholine, an important neurotransmitter, says Dr. Parikh. Acetylcholine is involved in the initiation of REM sleep (i.e., the sleep stage most commonly associated with dreaming), so if those neurons are inhibited, you may have trouble falling and staying asleep. Luckily, this side effect is rare.
It can also turn kids into little insomniacs, says Boomershine. Having them take the long-acting med earlier in the day won't help either since it lasts all day. Talk to their pediatrician about making a switch.It's incredibly rare, according to the National Institutes of Health, but keep it on your radar anyway. While you may be taking Zyrtec to prevent allergy symptoms, it's possible to have a potentially deadly allergic reaction called anaphylaxis from the medication itself. (FYI: This is a risk with all medications, not just Zyrtec.) If you develop hives, swelling, shortness of breath, wheezing, and chest tightness, call 911 immediately.
(Psst: Looking for the best allergy med, according to allergy doctors? Get their verdict here.)If you experience a sore throat while taking Zyrtec, it's likely because your mucous membranes, the inner lining of your body and organs, become drier, causing the tissue in your mouth to also feel more parched and lead to a sore throat, says Dr. Eitches. And coughing can be an instinctive response to try to moisten the mouth.
To combat this, stay hydrated. But if this side effect becomes too severe, Dr. Eitches suggests switching to a different antihistamine.Constipation is a very rare side effect that happens due to a drug's anticholinergic effect, which means the drug blocks neurotransmitters that affect how the body functions. In this case, certain receptors that help gut motility are blocked. This side effect was much more common with older, first-generation antihistamines such as Benadryl, says Dr. Patel.
It's not as common with Zyrtec, but if this does happen to you, Dr. Eitches recommends trying a different antihistamine, adding fiber to your diet, and staying well-hydrated to get things moving again.Anxiety is another super rare side effect of Zyrtec, but it is possible, says Dr. Parikh. Remember acetylcholine? Turns out blocking it may also trigger anxiety and fast heart rate because acetylcholine regulates heart contractions and blood pressure as well.
You should stop feeling antsy once you discontinue the medication, but if quitting it is not an option, talk with your doctor about other drugs that can help you manage your allergies, notes Dr. Parikh.As of May 2025, the FDA issued an alert that discontinuing Zyrtec after long-term use may result in severe pruritus (or, itchiness) within a few days. It's rare, but can sometimes require medical intervention.
"I always counsel my patients who have been on Zyrtec for long periods of time to taper the medication off slowly," says Maria Shtessel, MD, an allergist and immunologist at Mount Sinai. "For example, [they can start by] taking it first every other day, and increasing the days between doses slowly before completely stopping."Yep. "When taken in the recommended doses, antihistamines can be taken daily. This is especially true with Zyrtec, since it doesn't show decreasing effectiveness if used daily," says Sima Patel, MD, an allergist at New York Allergy & Sinus Centers.
Still, it's probably worth holding off on medication that you don't need, says Dr. Patel. So if you aren't having allergy symptoms or they get milder during a certain time of the year, that's probably a good time to take a Zyrtec break. "We always want the least amount of medication to control symptoms. However, starting allergy medications two weeks prior to your symptomatic season is best to help prevent symptoms," Dr. Patel says.It depends on whether you experience any side effects, says Robert Eitches, MD, an allergist at Tower Allergy. If your problems are only during the day time and you aren't really prone to side effects, then go ahead and take it during the day.
But if you experience side effects like drowsiness, Dr. Eitches recommends taking your dose at night before bed. "That way you wake up in the morning relatively clearer too," he says. If it makes you sleepy, the side effect will have likely worn off by the time you wake up, and since the medication can provide relief for 24 hours, you'll still experience relief during the day.Zyrtec is safe for most people, but there are some individuals who should stay away. Children under 2, anyone with a history of an allergic reaction to Zyrtec or hydroxyzine/piperazine derivatives, and those with severe renal impairment shouldn't take Zyrtec, says Dr. Patel. If you are pregnant and breastfeeding, Dr. Patel recommends speaking to your doctor before using it.
The medication is "primarily eliminated from your body through the kidneys," says Dr. Parikh. So, if your kidneys aren't functioning properly, the medication can accumulate and build up in your blood, which may cause additional damage to your kidneys and severe side effects.
Additionally, if you take any medications that can cause sedation, such as benzodiazepines, you should talk with your doctor before taking Zyrtec, says Dr. Parikh, because combining the two may cause worsened side effects. Other antihistamines are typically okay to take with Zyrtec as long as they don't make you too sleepy, she adds. And it's always a good idea avoid alcohol when you're on Zyrtec.
When in doubt, go to your doctor with any questions before you take Zyrtec to quell allergy symptoms.
You Might Also Like
Jennifer Garner Swears By This Retinol Eye Cream
These New Kicks Will Help You Smash Your Cross-Training Goals
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns

Yahoo

time2 hours ago

  • Yahoo

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns

Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool

It's been a long road, but Blood Oxygen tracking is back for the newest Apple Watches in the US – but the feature isn't the same
It's been a long road, but Blood Oxygen tracking is back for the newest Apple Watches in the US – but the feature isn't the same

Yahoo

time2 hours ago

  • Yahoo

It's been a long road, but Blood Oxygen tracking is back for the newest Apple Watches in the US – but the feature isn't the same

When you buy through links on our articles, Future and its syndication partners may earn a commission. Following an 18-month ban, Blood Oxygen tracking is coming back to the Apple Watch Series 9, Series 10, and Ultra 2 It's not an entirely on-device experience anymore, though The Apple Watch still measures Blood Oxygen, but the iPhone will calculate and display the final result It's been a long 18 months, but Apple's announced that Blood Oxygen tracking and monitoring are returning to the Apple Watch Series 9, Series 10, and Ultra 2 in the United States. The feature was disabled and effectively banned on the Series 9 and Ultra 2 – then the Series 10, which launched later – after a ruling in January 2024 due to a patent dispute over the technology being used between Massimo and Apple. Now, thanks to iOS 18.6.1 and watchOS 11.6.1, which will roll out later today, the feature is returning in a 'redesigned' form. In its new iteration, the Apple Watch Series 9, Series 10, and Ultra 2's sensors can take a reading, then transmit the data to the connected iPhone, where it will be calculated and displayed in the Health app under 'Respiratory' readings. So no, you won't be able to take the reading, watch as it progresses, and then view the results right on your wrist, as you could before. Still, this does effectively return the tracking and monitoring functionality to the impacted Apple Watch models in the United States. In a statement shared, Apple explains the changes as: 'Users with these models in the U.S. who currently do not have the Blood Oxygen feature will have access to the redesigned Blood Oxygen feature by updating their paired iPhone to iOS 18.6.1, and their Apple Watch to watchOS 11.6.1. Following this update, sensor data from the Blood Oxygen app on Apple Watch will be measured and calculated on the paired iPhone, and results can be viewed in the Respiratory section of the Health app. This update was enabled by a recent U.S. Customs ruling.' The U.S. Customs ruling is key here, as this will return the feature to the Apple Watches sold when the ban began and was subsequently enforced. If you still have an older Apple Watch, or one sold prior to January 2024, the Blood Oxygen functionality remains unimpacted and won't be changed. That also goes for any models sold outside of the United States, which have been unimpacted by this ruling. Still, this does return the Blood Oxygen feature to the Apple Watch, even if it splits the experience between watch and phone. But this separation is likely key to having this allowed and approved by U.S. Customs. For those who have purchased an Apple Watch Series 9, 10, or Ultra 2 in those many months, this is a return to form and rounding out of the health tracking features on Apple's star wearable in the United States. Even in our Apple Watch Series 10 review, we noted that the Blood Oxygen tracking feature was missing in the US. Apple has a pretty smart rollout here, and considering rumors of further pushes into health features that we might see with future generations of Apple Watch models, it might be helpful to have these readings going straight into the Health app. Either route, though, if you've been waiting for Blood Oxygen tracking to return, it's back, but you'll want to make sure your iPhone is nearby if you want to see the results. While Apple has not shared an exact timing for the rollouts of iOS 18.6.1 and watchOS 11.6.1, it has promised to arrive today – August 14, 2025 – in the United States, and we'll update this piece when we see it rolling out. You might also like Constantly dismissing notifications on your Apple Watch? You're going to love Apple's watchOS 26 latest gesture I'm a fitness tracker expert, and here are my top 3 subscription-free picks for 2025 Garmin Venu X1 review: The most innovative Garmin watch in years, and a genuine Apple Watch Ultra rival

State Department Halts Medical Visas For Palestinians
State Department Halts Medical Visas For Palestinians

Yahoo

time3 hours ago

  • Yahoo

State Department Halts Medical Visas For Palestinians

Eight Palestinian children from Gaza named, Rahaf, Ibrahim, Jana, Mustafa, Nasser, Mohammed, Kenan, and Ahmed, arrive at O'Hare International Airport, sponsored by Palestine Children's Relief Fund (PCRF), for medical treatment in Chicago, Illinois, USA on December 2, 2024. Credit - Jacek Boczarski—Anadolu via Getty Images The State Department said it would stop issuing visas to Palestinians from Gaza, including to those coming to the United States for humanitarian and medical treatment, following a campaign by far-right political activist Laura Loomer. 'All visitor visas for individuals from Gaza are being stopped while we conduct a full and thorough review of the process and procedures used to issue a small number of temporary medical-humanitarian visas in recent days,' the U.S. State Department said in a statement on Saturday. The decision will impact several programs that have evacuated dozens of critically injured children from Gaza over the last 21 months, including amputees and severe burn victims. The announcement came just hours after a series of social media posts from Loomer criticizing the medical evacuations of Palestinian children to the U.S. In one post, she shared a video of a child amputee arriving in a wheelchair at Seattle airport for medical treatment, adding: 'The Trump administration needs to shut this abomination down ASAP.' Loomer, who once described herself as a 'proud Islamaphobe' and said 9/11 was an 'inside job,' made false claims in her posts and said she had sent her 'evidence' to Secretary of State Marco Rubio. Hours later, the pause was announced. Read more: I Can No Longer Feed Kids in Gaza Rubio told "Face the Nation" on CBS on Sunday that the action came after "outreach from multiple congressional offices asking questions about it." But Loomer quickly took credit for the pause, posting: 'It's amazing how fast we can get results from the Trump administration.' The Palestinian Children Relief Fund (PCRF), a charity that organizes medical evacuations of children to the U.S., said the move will prevent them from providing 'lifesaving medical treatment' for 'critically ill children' from Gaza. 'Medical evacuations are a lifeline for the children of Gaza who would otherwise face unimaginable suffering or death due to the collapse of medical infrastructure in Gaza,' the PCRF said in a statement. According to the World Health Organization (WHO), Gaza's health system has been in collapse, and there has been a 'relentless and systematic decimation of hospitals in Gaza.' The United Nations children's charity, UNICEF, said in July that more than 17,000 children have been killed and 33,000 injured in Gaza in the last 21 months. HEAL Palestine, another charity that organizes evacuations and which was specifically targeted by Loomer in her posts, said this month it has evacuated 63 injured children and 148 total evacuees to the U.S. to receive treatment. Earlier this month, it carried out the largest known evacuation of wounded children from Gaza to the U.S., which included 11 children and their families, most of them for treatment of amputations. HEAL Palestine made it clear on social media that the visas it uses to bring people to the U.S. for treatment were not for resettlement, but for lifesaving care, contrary to Loomer's claims. 'After their treatment is complete, the children and any accompanying family members return to the Middle East. This is a medical treatment program, not a refugee resettlement program,' HEAL Palestine said Saturday. The charity added that U.S. tax dollars do not fund the treatment provided to these children. Loomer, a conspiracy theorist with a history of using hate speech to gain attention, has acquired an outsized influence over the White House in President Donald Trump's second term. She has successfully lobbied to remove people from top government roles whom she considers disloyal to the president, including six from the National Security Council, a senior Customs and Border Protection official, and a Food and Drug Administration vaccine official. TIME has contacted the State Department for comment. Contact us at letters@ Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store